Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy

Rille Pihlak, Jamie MJ Weaver , Juan Valle, Mairead Mcnamara

Research output: Contribution to journalArticlepeer-review

Abstract

Abstract: Pancreatic ductal adenocarcinoma (PDAC) continues to be a disease with poor outcomes and short-lived treatment responses. New information is emerging from genome sequencing identifying potential subgroups based on somatic and germline mutations. A variety of different mutations and mutational signatures have been identified; the driver mutation in around 93% of PDAC is KRAS, with other recorded alterations being SMAD4 and CDKN2A. Mutations in the deoxyribonucleic acid (DNA) damage repair pathway have also been investigated in PDAC and multiple clinical trials are ongoing with DNA-damaging agents. Rare mutations in BRAF and microsatellite instability (MSI) have been reported in about 1-3% of patients with PDAC, and agents used in other cancers to target these have also shown some promise. Immunotherapy is a developing field, but has failed to demonstrate benefits in PDAC to date. While many trials have failed to improve outcomes in this deadly disease, there is optimism that by developing a better understanding of the translational aspects of this cancer, future informed therapeutic strategies may prove more successful.
Original languageEnglish
JournalCancers
Volume10
Issue number1
Early online date12 Jan 2018
DOIs
Publication statusPublished - 2018

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy'. Together they form a unique fingerprint.

Cite this